Edition:
United States

Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

68.47USD
3:14pm EST
Change (% chg)

$-0.49 (-0.71%)
Prev Close
$68.96
Open
$68.73
Day's High
$68.73
Day's Low
$68.01
Volume
652,804
Avg. Vol
435,246
52-wk High
$88.48
52-wk Low
$67.30

Select another date:

Tue, Dec 6 2016

Photo

Novartis' drug tops chemotherapy in untreated lung cancer patients

Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study.

Exclusive: Novartis in talks to sell some central nervous system drugs - sources

ZURICH Novartis is in talks about the sale of some older neuroscience drugs, people close to the matter said, as the Swiss drugmaker clears the decks to concentrate on promising new medicines it hopes will help to restore sales growth.

Pfizer blood cancer drug tops standard therapy for untreated patients

Pfizer Inc said on Monday its cancer drug, Bosulif, was found superior to Novartis AG's Gleevec in a late-stage study on untreated patients with a form of blood and bone marrow cancer characterized by abnormal white blood cells production.

Novartis CEO plays down prospects for Actelion bid: Blick

VIENNA Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction.

Novartis says 82 percent of leukemia patients in remission after CAR-T

An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday.

Novartis buys U.S. blood disease drugmaker in $665 million deal

ZURICH Novartis is buying U.S.-based Selexys Pharmaceuticals in a deal worth up to $665 million, the Swiss drugmaker said on Monday, expanding its pipeline of medicines to combat blood diseases.

UPDATE 1-Novartis buys US blood disease drugmaker in $665 mln deal

* Study results for drug being acquired due Dec. 4 (Adds analyst comment, details, background, shares)

Novartis says to pay up to $665 mln for U.S. blood disease drugmaker

ZURICH, Nov 21 Novartis said on Monday it was buying U.S.-based Selexys Pharmaceuticals in a deal worth up to $665 million, as the Swiss drugmaker expands its pipeline of medicines to combat blood diseases.

European shares seen slightly higher. For stock movers and more see the LiveMarkets blog

MILAN, Nov 21 Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets

Novartis backs off from 2016 date for testing Google autofocus lens

ZURICH Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily."

Select another date: